Loading...

Healius Limited

HLS.AXASX
Healthcare
Medical - Diagnostics & Research
A$0.74
A$-0.05(-5.73%)

Healius Limited (HLS.AX) Company Profile & Overview

Explore Healius Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Healius Limited (HLS.AX) Company Profile & Overview

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through four segments: Pathology, Imaging, Day Hospitals, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. It operates 2,105 pathology sites; 11 day hospital sites; and 134 imaging sites. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.

SectorHealthcare
IndustryMedical - Diagnostics & Research
CEOPaul D. Anderson

Contact Information

61 2 9432 9400
Liberty Place, Sydney, NSW, 2000

Company Facts

4,329 Employees
IPO DateAug 3, 1998
CountryAU
Actively Trading

Frequently Asked Questions

;